Literature DB >> 10340169

Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis.

D C Morrison1, R Silverstein, M Luchi, A Shnyra.   

Abstract

A substantial body of knowledge has emerged over the past several decades concerning the primary and tertiary, and quaternary structure of endotoxic LPS and their contribution to the pathogenesis of gram-negative sepsis; however, important questions remain. Among them are the precise three-dimensional configuration of the LPS macromolecule and the contribution of the quaternary structure to the ability of these potent microbial factors to interact with host humoral and cellular inflammatory mediator systems. Also remaining to be sufficiently addressed is the relative contribution of endotoxin interactions with the host to the overall manifestation of disease and conditions under which such contributions serve as the pivotal event in determining outcome. The answers to these questions can be expected to provide valuable insights into potential novel therapeutic intervention strategies and approaches that will ultimately reduce both morbidity and mortality in infection from gram-negative microbes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340169     DOI: 10.1016/s0891-5520(05)70077-5

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  13 in total

1.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Synthesis of a monophosphoryl lipid A derivative and its conjugation to a modified form of a tumor-associated carbohydrate antigen GM3.

Authors:  Qianli Wang; Jie Xue; Zhongwu Guo
Journal:  Chem Commun (Camb)       Date:  2009-08-27       Impact factor: 6.222

Review 3.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 4.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

5.  Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice.

Authors:  B Rearte; A Maglioco; L Balboa; J Bruzzo; V I Landoni; E A Laborde; P Chiarella; R A Ruggiero; G C Fernández; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

6.  Synthesis of a monophosphoryl derivative of Escherichia coli lipid A and its efficient coupling to a tumor-associated carbohydrate antigen.

Authors:  Shouchu Tang; Qianli Wang; Zhongwu Guo
Journal:  Chemistry       Date:  2010-01-25       Impact factor: 5.236

7.  Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance.

Authors:  B Rearte; V Landoni; E Laborde; G Fernández; M Isturiz
Journal:  Clin Exp Immunol       Date:  2009-11-12       Impact factor: 4.330

8.  Role for moesin in lipopolysaccharide-stimulated signal transduction.

Authors:  Iveta Iontcheva; Salomon Amar; Khalid H Zawawi; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Construction of Escherichia coli Mutant with Decreased Endotoxic Activity by Modifying Lipid A Structure.

Authors:  Qiong Liu; Yanyan Li; Xinxin Zhao; Xue Yang; Qing Liu; Qingke Kong
Journal:  Mar Drugs       Date:  2015-05-27       Impact factor: 5.118

10.  Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

Authors:  Yingying Xu; Pak-Wai Yuen; Jenny Ka-Wing Lam
Journal:  Pharmaceutics       Date:  2014-07-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.